Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11387MR)

This product GTTS-WQ11387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11387MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3844MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ15743MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ8124MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ5661MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ10517MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ3912MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ3334MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ179MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW